Vol 8, No 4 (2023)
Original article
Published online: 2023-09-18

open access

Page views 398
Article views/downloads 254
Get Citation

Connect on Social Media

Connect on Social Media

The model for end-stage liver disease excluding international normalized ratio (MELD-XI) predicts three-year mortality in patients with advanced heart failure

Kamila Kurkiewicz-Sawczak1, Zofia Gierlotka2, Mariusz Gąsior3, Bożena Szyguła-Jurkiewicz3
Medical Research Journal 2023;8(4):277-285.

Abstract

Introduction: Accurate risk stratification is an important element of management in patients with advanced heart failure (adHF).

Objectives: We aimed to determine factors associated with three–year mortality in patients with adHF who underwent qualification for heart transplantation.

Material and methods: We retrospectively analyzed the data of 417 consecutive adult patients with adHF hospitalized in the Cardiology Department between 2011 and 2017. We included patients with New York Heart Association classes III–IV with at least two episodes of proven congestion requiring high-dose intravenous diuretics in the last 12 months. Exclusion criteria were acute HF, inotropic support, any previous heart surgery, inflammatory diseases, chronic kidney and liver disease, severe obstructive pulmonary disease and hematologic, autoimmune or neoplastic diseases. We analysed prognostic value of the model for end-stage liver disease (MELD), which reflects multiorgan dysfunction. The primary endpoint was death during three years of follow-up.

Results: In the overall population of 293 patients the median age was 56 (51–61) years, and 92.8% of the patients were male. During the follow-up period, 160 patients reached the primary endpoint. The MELD-XI score hazard ratio (HR) 1.197;  95% CI (confidence interval) (1.131–1.267), p < 0.001), PLR value [HR 1.100;  95% CI (1.080–1.130), p < 0.001], uric acid [HR 1.013; 95% CI (1.002–1.024), p = 0.0169] and sodium HR 1.079; 95% CI (1.044–1.115), p < 0.001] serum concentrations were independent factors of three–year mortality.

Conclusions: Higher MELD-XI scores and PLR values as well as higher uric acid and lower serum sodium concentrations are associated with worse outcomes in patients with adHF.

Article available in PDF format

View PDF Download PDF file

References

  1. Crespo-Leiro MG, Metra M, Lund LH, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018; 20(11): 1505–1535.
  2. Dorrance A. Faculty Opinions recommendation of ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature. 2014.
  3. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the Diagnosis And Treatment of Acute And Chronic Heart Failure 2008. Revista Española de Cardiología (English Edition). 2008; 61(12): 1329.
  4. Szczurek W, Szyguła-Jurkiewicz B, Zakliczyński MW, et al. Prognostic value of selected risk scales in patients with end-stage heart failure. Kardiol Pol. 2018; 76(9): 1320–1326.
  5. Kim MS, Kato TS, Farr M, et al. Hepatic dysfunction in ambulatory patients with heart failure: application of the MELD scoring system for outcome prediction. J Am Coll Cardiol. 2013; 61(22): 2253–2261.
  6. Inohara T, Kohsaka S, Shiraishi Y, et al. West Tokyo Heart Failure Registry Investigators. Prognostic impact of renal and hepatic dysfunction based on the MELD-XI score in patients with acute heart failure. Int J Cardiol. 2014; 176(3): 571–573.
  7. Heuman DM, Mihas AA, Habib A, et al. MELD-XI: a rational approach to "sickest first" liver transplantation in cirrhotic patients requiring anticoagulant therapy. Liver Transpl. 2007; 13(1): 30–37.
  8. Samsky MD, Patel CB, DeWald TA, et al. Cardiohepatic interactions in heart failure: an overview and clinical implications. J Am Coll Cardiol. 2013; 61(24): 2397–2405.
  9. Myers RP, Cerini R, Sayegh R, et al. Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology. 2003; 37(2): 393–400.
  10. Gotou M, Suzuki A, Shiga T, et al. Implication of modified MELD scores for postdischarge prognosis in hospitalized patients with heart failure. Heart Vessels. 2023; 38(4): 535–542.
  11. Lin Z, Liu X, Xiao Li, et al. The MELD-XI score predicts 3-year mortality in patients with chronic heart failure. Front Cardiovasc Med. 2022; 9: 985503.
  12. Saito Y, Nakai T, Ikeya Y, et al. Prognostic value of the MELD-XI score in patients undergoing cardiac resynchronization therapy. ESC Heart Fail. 2022; 9(2): 1080–1089.
  13. Balta S, Ozturk C. The platelet-lymphocyte ratio: A simple, inexpensive and rapid prognostic marker for cardiovascular events. Platelets. 2015; 26(7): 680–681.
  14. Mann DL, Young JB. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest. 1994; 105(3): 897–904.
  15. Ferroni P, Vazzana N, Riondino S, et al. Platelet function in health and disease: from molecular mechanisms, redox considerations to novel therapeutic opportunities. Antioxid Redox Signal. 2012; 17(10): 1447–1485.
  16. Lindemann S, Krämer B, Seizer P, et al. Platelets, inflammation and atherosclerosis. J Thromb Haemost. 2007; 5 Suppl 1: 203–211.
  17. Prabhu S. Cytokine-Induced Modulation of Cardiac Function. Circulation Research. 2004; 95(12): 1140–1153.
  18. Azab B, Shah N, Akerman M, et al. Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction. J Thromb Thrombolysis. 2012; 34(3): 326–334.
  19. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation. 1986; 73(2): 257–267.
  20. Klein L, O'Connor CM, Leimberger JD, et al. OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005; 111(19): 2454–2460.
  21. Adrogué HJ. Hyponatremia in Heart Failure. Methodist Debakey Cardiovasc J. 2017; 13(1): 40.
  22. Rusinaru D, Tribouilloy C, Berry C, et al. MAGGIC Investigators. Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: an individual patient data meta-analysis(†): Meta-Analysis Global Group in Chronic heart failure (MAGGIC). Eur J Heart Fail. 2012; 14(10): 1139–1146.
  23. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation. 1986; 73(2): 257–267.
  24. Deubner N, Berliner D, Frey A, et al. Dysnatraemia in heart failure. Eur J Heart Fail. 2012; 14(10): 1147–1154.
  25. Yoo BS, Park JJ, Choi DJ, et al. COAST investigators. Prognostic value of hyponatremia in heart failure patients: an analysis of the Clinical Characteristics and Outcomes in the Relation with Serum Sodium Level in Asian Patients Hospitalized for Heart Failure (COAST) study. Korean J Intern Med. 2015; 30(4): 460–470.
  26. Tamariz L, Harzand A, Palacio A, et al. Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis. Congest Heart Fail. 2011; 17(1): 25–30.
  27. Filippatos GS, Ahmed MI, Gladden JD, et al. Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Heart J. 2011; 32(6): 712–720.
  28. Otaki Y, Watanabe T, Kinoshita D, et al. Association of plasma xanthine oxidoreductase activity with severity and clinical outcome in patients with chronic heart failure. Int J Cardiol. 2017; 228: 151–157.
  29. Yamamoto T, Moriwaki Y, Takahashi S, et al. Effect of norepinephrine on the urinary excretion of purine bases and oxypurinol. Metabolism. 2001; 50(10): 1230–1233.
  30. Desai RV, Ahmed MI, Fonarow GC, et al. Effect of serum insulin on the association between hyperuricemia and incident heart failure. Am J Cardiol. 2010; 106(8): 1134–1138.